P38 KINASE INHIBITORS REDUCE THE EXPRESSION OF DUX4 AND CATAROTIC GENES FOR THE TREATMENT OF PERITONEOSCABOBRACHIO MUSCLE DYSTROPHY (FSHD)
CY1125744T1Undetermined Publication Date: 2026-04-17FULCRUM THERAPEUTICS INC
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- CY20221100693T
- Authority / Receiving Office
- CY · CY
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-06-08
- Filing Date
- 2022-10-21
- Publication Date
- 2026-04-17
- Estimated Expiration
- 2042-10-21
Abstract
The disclosure relates to methods and compositions comprising p38 kinase inhibitors and agents that modulate the expression of DUX4 and catarrhal genes including but not limited to ZSCAN4, LEUTX, PRAMEF2, TRIM43, MBD3L2, KHDC1L, RFPL2, CCNA1, SLC34A2, TPRX1, PRAMEF20, TR1M49, PRAMEF4, PRAME6, PRAMEF15, or ZNF280A. Methods useful for the treatment of a disease associated with abnormal expression of DUX4 and catarrhal genes (e.g., peritoneo-scaphobrachial muscular dystrophy) are disclosed.
Need to check novelty before this filing date? Find Prior Art